5-Isobutyl-1,3-benzodioxole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 5-Isobutyl-1,3-benzodioxole
• 英文别名: 5-(2-methylpropyl)-1,3-benzodioxole
• 化学式: C₁₁H₁₄O₂
• 分子量: 178.23
• InChiKey: PCYRHVCROYSFSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] NOVEL INHIBITORS OF TRYPANOSOMA BRUCEI METHIONYL T-RNA SYNTHETASE (TB METRS) FOR THE TREATMENT OF AFRICAN TRYPANOSOMIASIS<br/>[FR] NOUVEAUX INHIBITEURS DE MÉTHIONYL T-ARN SYNTHÉTASE (TB METRS) DE TRYPANOSOMA BRUCEI POUR LE TRAITEMENT DE LA TRYPANOSOMIASE AFRICAINE
  申请人：UNIV TEXAS

  公开号：WO2016004297A1

  公开（公告）日：2016-01-07

  The present disclosure relates to compounds which can be used to treat sleeping sickness and infections of Trypanosoma brucei. The present disclosure also provides pharmaceutical compositions and methods of using the disclosed compounds. In some aspects, the present invention provides compounds of the formula: wherein: Rs is hydrogen, alkylcc-<:12), acylcc-s12J, substituted alkylcc-<:12), or substituted acylcc-s12J, or is taken together with R2 as described below; Rt, is alkylcc-<:12), cycloalkylcc-s12J, -alkanediylcc-s8)-cycloalkylcc-s12J, arylcc-<:12), heteroarylcc-<:12), aralkylcc-<:12), heterocycloalkylcc-s12J, acylcc-<:12), -alkanediylcc-s8)-heterocycloalkylcc-s12J.

  本发明公开了可用于治疗睡眠病和布鲁氏锥虫感染的化合物。本发明还提供了药物组合物以及使用所述化合物的方法。在某些方面，本发明提供了如下通式的化合物：其中：Rs为氢、烷基(C1-C12)、酰基(C1-C12)、取代的烷基(C1-C12)或取代的酰基(C1-C12)，或者与下文所述的R2一起考虑；Rt为烷基(C1-C12)、环烷基(C3-C12)、-烷二基(C2-C8)-环烷基(C3-C12)、芳基(C6-C12)、杂芳基(C5-C12)、芳烷基(C7-C12)、杂环烷基(C3-C12)、酰基(C1-C12)、-烷二基(C2-C8)-杂环烷基(C3-C12)。
• MODULATORS OF THE RELAXIN RECEPTOR 1
  申请人：The United States of America, as Represented by the Secretary, Dept. of Health & Human Services

  公开号：US20150119426A1

  公开（公告）日：2015-04-30

  Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R 1 , and R 2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.

  本文揭示了人类松弛素受体1的调节剂，例如，公式（I）中的A、R1和R2如本文所定义，这些调节剂在治疗哺乳动物松弛素受体1介导的人类健康方面，例如心血管疾病中是有用的。还公开了一种包含药用适宜载体和本公开的至少一种化合物的组合物，以及一种用于治疗介导人类松弛素受体1的哺乳动物健康方面的干预方法。
• NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
  申请人：Merck Patent GmbH

  公开号：US20160168090A1

  公开（公告）日：2016-06-16

  The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚化合物及其药用可接受的组合物，用作P2X7拮抗剂，用于治疗与P2X7相关的疾病。
• Substituted bis-amide metalloprotease inhibitors
  申请人：Sucholeiki Irving

  公开号：US20070155739A1

  公开（公告）日：2007-07-05

  This invention relates to substituted bis-amide pyrimidine compounds of Formula (I), which are useful for the treatment of metalloprotease mediated diseases, in particular MMP-13 related diseases.

  这项发明涉及Formula (I)的取代双酰胺嘧啶化合物，这些化合物对于治疗金属蛋白酶介导的疾病，特别是MMP-13相关疾病是有用的。
• NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US20170349575A1

  公开（公告）日：2017-12-07

  Novel chemokine CXCR1 and CXCR2 receptor antagonist compounds of general formula (I) are described. Also described, are pharmaceutical compositions including the compounds, and use of the compounds and the compositions for the treatment of chemokine-mediated pathologies, more specifically in the field of dermatology.

  描述了一种通用式（I）的新型趋化因子CXCR1和CXCR2受体拮抗剂化合物。还描述了包括这些化合物的药物组合物，以及用于治疗趋化因子介导的病理生理学，更具体地说是在皮肤病学领域中使用这些化合物和组合物的方法。